Response to Immune Checkpoint Inhibitor Treatment in Advanced Cervical Cancer and Biomarker Study

Background: Checkpoint inhibitor immunotherapy or immuno-oncology (IO) treatment in refractory cervical cancer yielded an objective response rate (ORR) of 12% in tumors expressing the programmed cell death ligand-1 (PD-L1) in the KEYNOTE-158 phase II study. We hypothesized that the positive response...

Full description

Bibliographic Details

Published in:	Frontiers in Medicine
Main Authors:	Kevin R. Shieh, Anna Huang, Yiqing Xu
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-08-01
Subjects:	cervical cancer immunotherapy checkpoint inhibitor PD-L1 tumor mutation burden biomarker
Online Access:	https://www.frontiersin.org/articles/10.3389/fmed.2021.669587/full